Inclusion Criteria:

• Voluntarily signed consent.
• Age of ≥ 18 and ≤ 80 years.
• Received sufficient prior lines of myeloma therapy.
• Received treatment with at least one proteasome inhibitor, one IMiD and daratumumab.
• The patients should have measurable disease per IMWG definition.
• Estimated life expectancy > 12 weeks.
• ECOG performance score 0-1.
• Patients should have reasonable CBC counts, renal and hepatic functions.
• Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis.
• Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception for at least 6 months after T cell infusion.
• Men must be willing to use effective and reliable method of contraception for at least 6 months after T cell infusion.

Exclusion Criteria:

• Pregnant or lactating women.
• HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection.
• Any uncontrolled active infection.
• AEs from previous treatment that have not recovered.
• Patients who have had anti-BCMA therapy.
• Patients who have graft versus host disease (GvHD).
• Patients have received stem cell transplantation less than 12 weeks before leukapheresis.
• Patients have received any anti-cancer treatment before leukapheresis.
• Patients have received steroids before leukapheresis or lymphodepletion.
• Patients have plasma cell leukemia, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or clinically significant symptomatic immunoglobulin light chain (AL) amyloidosis with evidence of end-organ damage.
• Patients have been administered live attenuated vaccine before leukapheresis or lymphodepletion.
• Patients allergic to Flu, Cy, tocilizumab, dimethyl sulfoxide (DMSO) or CT053 CAR BCMA T cell.
• Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients.
• Patients have clinical significant pulmonary conditions.
• Patients are known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy.
• Patients with second malignancies in addition to MM are not eligible.
• Patients have central nervous system (CNS) metastases or CNS involvement.
• Patients have significant neurologic disorders.
• Patients are unable or unwilling to comply with the requirements of clinical trial.

Eligibility last updated 11/24/21. Questions regarding updates should be directed to the study team contact.